Title: First-in-Class potent and selective oral KAT6A degrader development candidate, PRT13722, drives complete tumor regressions as a monotherapy with an improved preclinical hematological safety profile.

Abstract Control Number: 7335

Session Title: Proximity-Induced Drug Discovery 2

Session Start Time: 4/21/2026 2:00 PM PT

Location: Poster Section 15

Poster Board Number: 20

Presentation Number: 5793

Summary:

  • PRT13722 is a highly differentiated, first-in-class, orally bioavailable, potent and highly selective KAT6A degrader development candidate.
  • PRT13722, by degrading KAT6A, drives more complete disruption of KAT6A regulatory pathways than dual KAT6A/B inhibitors, resulting in more robust depth and breadth of preclinical efficacy in HR+/HER2- breast cancer.
  • PRT13722 drives durable complete tumor regressions in HR+/HER2- xenograft models (both endocrine therapy (ET) sensitive and experienced) at well-tolerated doses, as a monotherapy.
  • PRT13722 is synergistic with ET, CDK4/6 inhibitors, and PI3Kα inhibitors while maintaining monotherapy and combination activity across HR+ BC models, including estrogen receptor 1 mutated and acquired therapy-resistant cancer cells.
  • PRT13722 has an improved preclinical hematological safety profile compared to prifetrastat, which may enable combinations with standard of care agents in HR+ BC.
  • PRT13722 is on track for IND filing in mid-2026.